B

BeOne

Global oncology therapeutics discovery, development, manufacturing

Global Strategic Feasibility and Study Start-Up Senior Director - Global Strategic Feasibility and Study Start Up

Full-Time
$206.2k - $276.2k/yr+ Annual bonus + Discretionary equity awards + Employee Stock Purchase Plan
Expert
Bachelor's, Master's, MBA, PhD
Remote in USA
RemoteTravel as needed.
Biology & BiotechClinical Research Operations

About the job

Requirements
  • Experience with study optimization vendors, tools, and methods.
  • Experience managing processes and timelines associated with Study Start-Up documentation, including Informed Consent development, Lab Manual creation, and Investigator Brochures.
  • Demonstrated process improvement experience, including mapping processes, measuring components, and delivering standardization and efficiency.
  • Proven experience in data analysis and interpretation to inform decision-making.
  • Expertise in principles driving country and site identification, feasibility, and study start-up strategies.
  • Demonstrated experience managing, influencing, building relationships, and achieving results with senior partners in an environment with competing priorities.
  • Strong understanding of clinical study operations, feasibility assessment, and global clinical development processes.
  • Ability to lead and inspire teams and foster a collaborative, results-oriented culture; experience managing cross-functional teams and working in a matrix environment.
  • Demonstrated ability to think strategically and make informed decisions based on comprehensive feasibility assessments and business objectives.
  • Bachelor’s degree or higher in a scientific, medical, or healthcare discipline.
  • For a BA or BS, 12 or more years of experience in feasibility, clinical study management, personnel management, and operations management; alternatively, for an MA or MS, 8 or more years of experience in those areas.
  • Prior experience in a leadership capacity is essential.
  • Proficiency with Microsoft Office Suite, CTMS applications, EDC applications, analytic tools such as Citeline and Studytrove, and additional feasibility software.
Responsibilities
  • Oversee global strategic feasibility proposals for global clinical studies in alignment with corporate objectives, therapeutic areas, and regional requirements.
  • Ensure global standardization of data documentation, data assets, tools, and processes to support quality decision-making at therapeutic area, indication, program, and study levels.
  • Drive process optimization initiatives to enhance feasibility assessment methodologies, tools, and metrics for efficiency, quality, and scalability.
  • Collaborate with internal stakeholders, including Clinical Operations, Clinical Development, Medical Affairs, Regulatory Affairs, and Biostatistics, to align and provide strategic input for study design and execution.
  • Establish and maintain partnerships with external organizations, including vendors, investigative sites, and key opinion leaders, to enhance study feasibility and optimize resources.
  • Build, lead, and mentor a high-performing team of feasibility and study start-up professionals, fostering a collaborative and innovative work environment.
  • Identify potential risks and challenges in study feasibility and develop mitigation strategies to minimize their impact on timelines, budget, and study success.
  • Prepare and present feasibility process and tool development progress, metrics, and recommendations to senior management and key stakeholders.
  • Participate in global projects representing Global Clinical Operations and the Global Strategic Feasibility team to support BeOne R&D goals.
  • Line-manage members of the global strategic feasibility team and drive ownership and accountability within the team and with external stakeholders.
  • Oversee strategic planning and feasibility assessments for global clinical studies.
  • Ensure global and country-level strategic feasibility during study planning to support execution, high-quality study start-up documentation, and predictable enrollment forecasts based on data analytics and company performance curves.
  • Establish and improve global strategic feasibility processes, procedures, and systems, as well as study start-up documentation, for continuous optimization.
  • Travel as needed.
Desired Qualifications
  • Knowledge of multiple therapeutic areas.
  • An advanced degree, such as an MSc, PhD, or MBA.

About the company

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Get referred to BeOne

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 25, 2026 FDA approval expanded TEVIMBRA in first-line HER2-positive gastroesophageal cancer.
  • August 31, 2026 Phase 3 survival data strengthened ZIIHERA-containing regimens.
  • Q2 2026 revenue hit $1.7 billion; management raised 2026 guidance to $6.8 billion.

What critics are saying

  • BeOne accepted developed-market pricing parity and Medicaid rebates on future U.S. approvals.
  • Zydus' BRUKINSA ANDA lawsuit targets patents; a 2034 composition patent remains the fortress.
  • AbbVie's trade-secrets case over BGB-16673 still threatens the BTK-degrader franchise.

What makes BeOne unique

  • BeOne built 35-plus assets and 93 trials across 1,100 U.S. sites by September 2026.
  • BRUKINSA dominates revenue, with 2026 global sales above $1.2 billion quarterly.
  • Hopewell, New Jersey gives BeOne U.S. manufacturing, R&D, and packaging capacity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • 401(k) Retirement Plan
  • Wellness Program
  • Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

8%

1 year growth

-6%

2 year growth

-1%
Associated Press
Oct 6th, 2026
Onco360 partners with BeOne Medicines to distribute Beqalzi for relapsed mantle cell lymphoma

Onco360, an independent specialty pharmacy, has been selected as a pharmacy partner by BeOne Medicines for Beqalzi (sonrotoclax). The drug is indicated for treating adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor. Beqalzi is a BCL-2 protein inhibitor. In a Phase 1/2 study of 103 adult patients with relapsed/refractory mantle cell lymphoma, the drug achieved an overall response rate of 52.4%, with a median time to response of 1.9 months. The median duration of response was 15.8 months. Onco360 is headquartered in Louisville, Kentucky, and operates as a flagship brand of PharMerica Corporation.

Yahoo Finance
Sep 4th, 2026
BeOne secures US pharma-tariff exemption after $1B+ manufacturing investment, but pricing concessions raise margin concerns

BeOne Medicines secured an exemption from Section 232 pharmaceutical tariffs through a voluntary agreement with the US government. The deal recognises over $1 billion in US manufacturing investment, including a $300 million expansion in Hopewell, New Jersey. The exemption protects BeOne from import duties on patented pharmaceuticals and ingredients. However, the company committed to pricing future FDA-approved medicines in line with other developed markets and participating in the Medicaid GENEROUS Model, which uses supplemental rebates. The Hopewell expansion will add small-molecule manufacturing and packaging capacity, creating approximately 120 full-time jobs. The facility will support a portfolio of more than 35 assets. Whilst the tariff exemption reduces supply-chain risk, international reference pricing commitments could limit pricing flexibility for future oncology medicines. Neither the tariff savings nor the financial impact of pricing concessions was disclosed.

Yahoo Finance
Aug 13th, 2026
Revolution Medicines shares rise 6.2% on BeOne-funded Phase 3 RAS(ON) deal

Revolution Medicines has partnered with BeOne Medicines in a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors. The August 2026 deal grants BeOne exclusive development and commercialisation rights in select Asian markets and commits BeOne to fund a global Phase 3 trial. Revolution Medicines reported a net loss of $644.37 million in Q2 2026 and $1.1 billion over six months. The company currently generates no revenue but projects $2.3 billion in revenue and $402.5 million in earnings by 2029. The partnership shifts near-term risk by offloading Phase 3 costs whilst providing access to milestone and royalty potential. However, the core investment case remains unchanged: regulatory progress and commercialisation of daraxonrasib, with trial execution and spending presenting the biggest risks.

Yahoo Finance
Aug 5th, 2026
BeOne Medicines Q2 revenue up 30% to $1.7B as BRUKINSA sales top $1.2B globally

BeOne Medicines reported second-quarter revenue of $1.7 billion, up 30% year over year, with GAAP earnings per ADS rising 144% to $2.05. The company's BTK inhibitor BRUKINSA generated more than $1.2 billion in global sales, increasing 31% from the prior year. The company raised its 2026 revenue guidance to CNY 6.6 billion–CNY 6.8 billion and expects GAAP operating income of CNY 1 billion–CNY 1.1 billion. Free cash flow doubled year over year to CNY 435 million. BeOne received FDA approval for Beqalzi in relapsed or refractory mantle cell lymphoma and reported positive Phase III results for a chemotherapy-free BRUKINSA regimen. US BRUKINSA sales totalled $893 million, up 31%, driven by demand in chronic lymphocytic leukaemia and non-CLL indications.

Yahoo Finance
Jul 23rd, 2026
BeOne CEO sells $34.6M in stock while retaining 50M+ shares

John Oyler, chief executive officer of BeOne Medicines AG, sold 109,713 American Depositary Shares worth $34.6 million on 20 and 21 July 2026, according to SEC filings. The transactions were executed under a Rule 10b5-1 trading plan adopted in March 2026. Despite the sale, Oyler retains a substantial ownership position exceeding 50.4 million total shares through various holdings. These include 28.2 million shares held through Oyler Investment LLC and 9.5 million shares in a Roth IRA account. The shares were sold at a weighted average price of $315.28. BeOne Medicines is a commercial-stage oncology biopharmaceutical company with $5.7 billion in trailing twelve-month revenue and a market capitalisation of $34.2 billion.